Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03998670
Other study ID # IXT6
Secondary ID 2UG1EY011751
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2019
Est. completion date July 30, 2020

Study information

Verified date September 2023
Source Jaeb Center for Health Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this short-term, pilot randomized trial comparing spectacles with relieving prism to spectacles without prism is to determine whether to proceed to a full-scale, longer-term randomized trial. This decision will be based primarily on assessing the initial (8-week) response to prism by comparing treatment groups on the following outcomes: - Mean distance intermittent exotropia (IXT) control score (the mean of 3 control scores) (primary outcome) - The proportion of participants demonstrating a "treatment response," defined as ≥1 point improvement in the mean distance IXT control score without spontaneous exotropia during control testing (secondary outcome) - The proportion of participants reporting adverse effects and good/excellent spectacle wear compliance


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date July 30, 2020
Est. primary completion date July 30, 2020
Accepts healthy volunteers No
Gender All
Age group 3 Years to 13 Years
Eligibility Inclusion Criteria: Intermittent Exotropia meeting all of the following criteria: - Age 3 to 13 years - Mean distance control score of =2.00 points with at least 1 measure of 3, 4, or 5 points (i.e, spontaneous tropia) from the 3 assessments during the exam - A near control score =4 on at least 1 of 3 assessments (cannot have score of 5, 5, 5) - Distance exodeviation between 16 Prism Diopters (?) and 35 ? (inclusive) by PACT - Near exodeviation between 10 ? and 35 ? (inclusive) by PACT - Near deviation does not exceed distance deviation by more than 10 ? by PACT (i.e., convergence insufficiency-type IXT excluded) - Refractive error between -6.00 Diopters (D) spherical equivalent (SE) and +2.50 D SE (inclusive) (based on a cycloplegic refraction performed within 7 months but prior to the day of enrollment) - Refractive correction (must be worn for at least 1 week if refractive error meets any of the following (based on a cycloplegic refraction performed within 7 months but prior to the day of enrollment): - SE anisometropia =1.00 D - Astigmatism =1.00 D in either eye - SE myopia =-0.50 D in either eye - If spectacles have been prescribed and are worn, they must meet the following pre- enrollment criteria: - SE anisometropia corrected to within 1.00 D of full SE anisometropic difference - Astigmatism corrected to within 1.00 D of full magnitude; axis within 10 degrees if astigmatism =1.00 D and axis within 5 degrees if astigmatism >1.00 D Exclusion Criteria: - Dissociated vertical deviation (DVD) - Vertical deviation >3 ? in primary gaze at distance or near - Patterns (such as an "A" or "V" pattern) with a downgaze measurement of >10 ? difference from straight ahead by PACT, measured per investigator's routine method - Treatment for IXT or amblyopia (other than refractive correction) within the past 4 weeks, including vision therapy, orthoptics, patching, atropine, or other penalization - Substantial overminus spectacles (spectacles overminused by more than 1.00 D SE than the most recent cycloplegic refraction and also results in minus SE power in the spectacles; underplussing is allowed) within the past 4 weeks - Prior strabismus, intraocular, or refractive surgery (including BOTOX injection) - Previous use of prism spectacles Additional Eligibility Criteria for Randomization Based on Prism Adaptation Testing - Exodeviation by PACT while wearing "trial" relieving prism for 30 minutes is smaller at distance or near than measured during initial testing (e.g. not fully adapting to prism at both distances) - No new esotropia on cover test at near while wearing "trial" relieving prism for 30 minutes, compared with enrollment measurement taken without prism - No esodeviation >6 ? on PACT at near while wearing "trial" relieving prism for 30 minutes

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Prism Glasses
Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
Non-Prism Glasses
Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism

Locations

Country Name City State
United States Wilmer Eye Institute Baltimore Maryland
United States UAB Pediatric Eye Care; Birmingham Health Care Birmingham Alabama
United States Indiana School of Optometry Bloomington Indiana
United States Boston Children's Hospital Waltham Boston Massachusetts
United States Boston Medical Center Boston Massachusetts
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Illinois College of Optometry Chicago Illinois
United States Cincinnati Children's Hospital Cincinnati Ohio
United States Ohio State University College of Optometry Columbus Ohio
United States Pediatric Ophthalmology of Erie Erie Pennsylvania
United States Nova Southeastern University College of Optometry, The Eye Institute Fort Lauderdale Florida
United States Southern California College of Optometry Fullerton California
United States Midwestern University Eye Institute Glendale Arizona
United States Pediatric Ophthalmology, P.C. Grand Rapids Michigan
United States Texas Children's Hospital - Dept. Of Ophthalmology Houston Texas
United States University of Chicago Hyde Park Illinois
United States Indiana University School of Optometry Indianapolis Indiana
United States Gundersen Health System La Crosse Wisconsin
United States University of Kentucky Department of Neurology Lexington Kentucky
United States Arkansas Childrens Little Rock Arkansas
United States Vanderbilt University Medical Center Nashville Tennessee
United States Virginia Pediatric Eye Center Norfolk Virginia
United States University of Nebraska Medical Center Omaha Nebraska
United States Salus University/Pennsylvania College of Optometry Philadelphia Pennsylvania
United States Western University College of Optometry Pomona California
United States OHSU Casey Eye Institute Portland Oregon
United States Houston Eye Associates The Woodlands Texas
United States Wolfe Eye Clinic West Des Moines Iowa

Sponsors (3)

Lead Sponsor Collaborator
Jaeb Center for Health Research National Eye Institute (NEI), Pediatric Eye Disease Investigator Group

Country where clinical trial is conducted

United States, 

References & Publications (2)

Hatt SR, Leske DA, Holmes JM, Henderson RJ, Chandler DL, Morrison DG, Summers AI, Cotter SA. Testing depth of suppression in childhood intermittent exotropia. J AAPOS. 2022 Feb;26(1):36-38.e1. doi: 10.1016/j.jaapos.2021.08.303. Epub 2021 Nov 16. — View Citation

Summers AI, Morrison DG, Chandler DL, Henderson RJ, Chen AM, Leske DA, Walker KR, Li Z, Melia BM, Bitner DP, Kurup SP, Allen M, Phillips PH, Nash DL, Grigorian AP, Kraus CL, Miller AM, Titelbaum JR, Kraker RT, Holmes JM, Cotter SA; Pediatric Eye Disease I — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Distance Visual Acuity (Snellen Equivalent) Distance visual acuity will be assessed at the 8-week outcome exam. Any optotype method can be used for testing. The distribution of distance visual acuity Snellen Equivalents will be tabulated for each treatment group. A lower Snellen Equivalent is best. 8 Weeks
Other Fusional Convergence - Continuous Break Point As an exploratory analysis, the distribution of fusional convergence amplitude (break point, blur point, and recovery) at 8 weeks will be summarized for each treatment group. Fusional amplitudes are a measure of how well a participant can converge their eyes using fusional vergence. It is measured by increasing base-out prism to the point that the participant is no longer able to control the deviation. The total amount of fusion is the magnitude of the base-out prism the participant was able to overcome plus the magnitude of the deviation. A higher number of prism diopters for break point is better than a lower number. A lower number for recovery point is better than a higher number. 8 Weeks
Other Suppression The suppression assessment is a standardized method of assessing the depth of suppression experienced while the participant is tropic (NOT aligned). Scoring is reported on an ordinal scale from 0 (no suppression) to 3 (dense suppression). "Missing" refers to cases in which participants were unable to understand the test and/or gave unreliable responses. As an exploratory analysis, the distribution of suppression level (none, mild, moderate, severe, missing) will be tabulated after 8 weeks by treatment group. 8 Weeks
Other Fusional Convergence - Continuous Recovery Point As an exploratory analysis, the distribution of fusional convergence amplitude (break point, blur point, and recovery) at 8 weeks will be summarized for each treatment group. Fusional amplitudes are a measure of how well a participant can converge their eyes using fusional vergence. It is measured by increasing base-out prism to the point that the participant is no longer able to control the deviation. The total amount of fusion is the magnitude of the base-out prism the participant was able to overcome plus the magnitude of the deviation. A higher number of prism diopters for break point is better than a lower number. A lower number for recovery is better than a higher number. 8 Weeks
Primary Exotropia Control Score at Distance, Continuous Score The primary analysis will be an intent-to-treat comparison of mean 8-week control of the distance exodeviation (average of 3 measurements) between treatment groups using an analysis of covariance (ANCOVA) model, which adjusts for baseline distance control. Distance control scores range from 0 to 5 with higher scores indicating a worse outcome. 8 weeks
Secondary Exotropia Control Score at Distance, % With Treatment Response The secondary analysis will calculate the percentage of participants with a "treatment response," defined as =1 point improvement in control of their distance exodeviation (average of 3 measurements) between baseline and the 8-week outcome exam. 8 weeks
Secondary Exotropia Control Score at Distance and Near, % With No Spontaneous Tropia The proportion of participants with no spontaneous tropia at 8 weeks will be compared between treatment groups using a two-sided Barnard's test with alpha of 0.05, with calculation of a two-sided 95% confidence interval on the difference in proportions.
No spontaneous tropia at the 8-week primary outcome exam is defined as a score of =2 (0, 1, or 2) on all three assessments of control at distance and at near.
8 Weeks
Secondary Exotropia Control Score at Distance, Continuous Change Between Baseline and 8 Weeks Control of the exodeviation was measured at distance using the IXT Office Control Score, (Mohney, 2006) which ranges from 0 (phoria) to 5 (constant exotropia). Control levels 3-5 were assigned based on the duration of manifest exotropia during a 30-second period before any dissociation. If no exotropia was observed, control levels 0-2 were assigned based on the longest time to reestablishing fusion after 3 consecutive 10-second periods of dissociation. Control was measured at the beginning, middle, and end (3 tests) of a 20- to 40-minute office examination, and the mean was used. The change in distance control from baseline to 8 weeks will be calculated. A negative value indicates improvement. 8 Weeks
Secondary Exotropia Control Score at Near, Continuous Score Near control will be evaluated similarly to the primary outcome and outcome measures 2-4. Near control scores range from 0 to 5 with higher scores indicating a worse outcome. 8 Weeks
Secondary Exodeviation by PACT at Distance, Continuous The measure of ocular alignment at distance by PACT will be summarized at 8 weeks for each treatment group. A higher deviation is worse. 8 Weeks
Secondary Exodeviation by PACT at Near, Continuous The measure of ocular alignment at near by PACT will be summarized at 8 weeks for each treatment group. A higher deviation is worse. 8 Weeks
Secondary Randot Preschool Stereoacuity at Near, Continuous Randot® Preschool Stereoacuity test (Stereo Optical Co., Inc., Chicago, IL). For analysis, stereoacuity was converted from seconds of arc scores to log arcsec values (in parentheses) as follows: 40 (1.60), 60 (1.78), 100 (2.00), 200 (2.30), 400 (2.60), 800 (2.90); participants with no detectable (nil) stereoacuity were assigned the value of 1600 (3.20). The measure of Randot Preschool Stereoacuity at near will be summarized at 8 weeks for each treatment group. A lower score is better. 8 Weeks
Secondary Compliance of Spectacle Wear Parents will be asked to complete a compliance calendar by recording the percentage of time their child has worn the study-prescribed spectacle correction each day. Proportion of time worn each day will be described as excellent (76% to 100%), good (51% to 75%), fair (26% to 50%), poor (1 to 25%), or none (0%). Based on review of the calendars and discussion with parents at the 8-week outcome exam, the investigator will record the total proportion of time worn as excellent (76% to 100%), good (51% to 75%), fair (26% to 50%), poor (1 to 25%), or none (0%: did not fill prescription or never picked up spectacles).
The distribution of compliance will be assessed for each treatment group at the outcome exam.
8 weeks
Secondary Child Assessment of Symptoms - Do Your Eyes Hurt? Adverse symptoms of intermittent exotropia will be summarized at the 8-week outcome exam using a symptom survey that is administered to the child. Response options are based on frequency of observations: never, sometimes, and always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks. 8 Weeks
Secondary Child Assessment of Symptoms - Do Your Eyes Feel Funny? Adverse symptoms of intermittent exotropia will be summarized at the 8-week outcome exam using a symptom survey that is administered to the child. Response options are based on frequency of observations: never, sometimes, and always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks. 8 Weeks
Secondary Child Assessment of Symptoms - Do You Have Double Vision? Adverse symptoms of intermittent exotropia will be summarized at the 8-week outcome exam using a symptom survey that is administered to the child. Response options are based on frequency of observations: never, sometimes, and always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks. 8 Weeks
Secondary Child Assessment of Symptoms - Is it Hard for You to Stare at Things? Adverse symptoms of intermittent exotropia will be summarized at the 8-week outcome exam using a symptom survey that is administered to the child. Response options are based on frequency of observations: never, sometimes, and always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks. 8 Weeks
Secondary Child Assessment of Symptoms - Do You Have Problems With Your Eyes in the Sun? Adverse symptoms of intermittent exotropia will be summarized at the 8-week outcome exam using a symptom survey that is administered to the child. Response options are based on frequency of observations: never, sometimes, and always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks. 8 Weeks
Secondary Child Assessment of Symptoms - Do Your Eyes go in and Out? Adverse symptoms of intermittent exotropia will be summarized at the 8-week outcome exam using a symptom survey that is administered to the child. Response options are based on frequency of observations: never, sometimes, and always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks. 8 Weeks
Secondary Child Assessment of Symptoms - Is it Hard to Focus Your Eyes? Adverse symptoms of intermittent exotropia will be summarized at the 8-week outcome exam using a symptom survey that is administered to the child. Response options are based on frequency of observations: never, sometimes, and always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks. 8 Weeks
Secondary Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Had Headaches? Adverse symptoms of intermittent exotropia and spectacle wear will be summarized at the 8-week outcome exam using a symptom survey that is administered to the parent.
Response options are based on frequency of observations: never, almost never, sometimes, often, and almost always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks.
8 Weeks
Secondary Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Had Eyestrain? Adverse symptoms of intermittent exotropia and spectacle wear will be summarized at the 8-week outcome exam using a symptom survey that is administered to the parent.
Response options are based on frequency of observations: never, almost never, sometimes, often, and almost always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks.
8 Weeks
Secondary Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Avoided Reading or Doing Things up Close? Adverse symptoms of intermittent exotropia and spectacle wear will be summarized at the 8-week outcome exam using a symptom survey that is administered to the parent.
Response options are based on frequency of observations: never, almost never, sometimes, often, and almost always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks.
8 Weeks
Secondary Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Reported Blurry Vision? Adverse symptoms of intermittent exotropia and spectacle wear will be summarized at the 8-week outcome exam using a symptom survey that is administered to the parent.
Response options are based on frequency of observations: never, almost never, sometimes, often, and almost always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks.
8 Weeks
Secondary Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Looked Over His or Her Spectacles? Adverse symptoms of intermittent exotropia and spectacle wear will be summarized at the 8-week outcome exam using a symptom survey that is administered to the parent.
Response options are based on frequency of observations: never, almost never, sometimes, often, and almost always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks.
8 Weeks
Secondary Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Taken His/Her Spectacles Off When he/She Should be Wearing Them? Adverse symptoms of intermittent exotropia and spectacle wear will be summarized at the 8-week outcome exam using a symptom survey that is administered to the parent.
Response options are based on frequency of observations: never, almost never, sometimes, often, and almost always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks.
8 Weeks
Secondary Parent Assessment of Symptoms and Spectacle Wear - Has Your Child Complained That the Spectacles Hurt His/Her Ears and/or Nose? Adverse symptoms of intermittent exotropia and spectacle wear will be summarized at the 8-week outcome exam using a symptom survey that is administered to the parent.
Response options are based on frequency of observations: never, almost never, sometimes, often, and almost always. The distribution of scores on each survey item will be tabulated by treatment group after 8-weeks.
8 Weeks

External Links